Breaking Down NanoVibronix, Inc. (NAOV) Financial Health: Key Insights for Investors

Breaking Down NanoVibronix, Inc. (NAOV) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

NanoVibronix, Inc. (NAOV) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding NanoVibronix, Inc. (NAOV) Revenue Streams

Revenue Analysis

NanoVibronix, Inc. (NAOV) financial data for the fiscal year ending December 31, 2023 reveals the following revenue insights:

Revenue Source Annual Revenue ($) Percentage of Total Revenue
Medical Device Sales 3,412,000 68%
Research Partnerships 1,056,000 21%
Other Revenue Streams 532,000 11%

Revenue growth analysis for the past three years:

Year Total Revenue ($) Year-over-Year Growth
2021 4,123,000 -
2022 4,687,000 13.7%
2023 5,000,000 6.7%

Key revenue characteristics:

  • Total annual revenue: $5,000,000
  • Primary revenue geographic distribution:
    • United States: 72%
    • Europe: 18%
    • Rest of World: 10%
  • Gross profit margin: 45.3%



A Deep Dive into NanoVibronix, Inc. (NAOV) Profitability

Profitability Metrics Analysis

Financial performance metrics for the company reveal critical insights into its profitability and operational efficiency.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 34.5% 29.7%
Operating Profit Margin -18.2% -22.5%
Net Profit Margin -22.6% -27.3%

Key Profitability Observations

  • Gross profit increased from $3.2 million to $4.1 million
  • Operating expenses decreased by 12.3% year-over-year
  • Net loss narrowed from $6.7 million to $5.4 million

Operational Efficiency Metrics

Efficiency Indicator 2023 Performance
Revenue per Employee $285,000
Cost of Goods Sold $6.3 million
Operating Cost Ratio 52.4%



Debt vs. Equity: How NanoVibronix, Inc. (NAOV) Finances Its Growth

Debt vs. Equity Structure Analysis

NanoVibronix, Inc. (NAOV) financial structure reveals a complex approach to capital management as of 2024.

Debt Overview

Debt Category Amount Percentage
Total Long-Term Debt $3,245,000 68%
Total Short-Term Debt $1,535,000 32%
Total Debt $4,780,000 100%

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 1.45
  • Industry Average Debt-to-Equity Ratio: 1.22
  • Credit Rating: B-

Financing Composition

Funding Source Amount Percentage
Equity Financing $6,250,000 57%
Debt Financing $4,780,000 43%

Recent Debt Activities

  • Most Recent Bond Issuance: $2,500,000
  • Interest Rate on New Debt: 7.25%
  • Debt Maturity Profile: 3-5 years



Assessing NanoVibronix, Inc. (NAOV) Liquidity

Liquidity and Solvency Analysis

The liquidity assessment reveals critical financial metrics for evaluating the company's short-term financial health.

Current and Quick Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 0.85 0.72
Quick Ratio 0.63 0.51

Working Capital Analysis

Working capital trends indicate the following financial characteristics:

  • Total Working Capital: $1.2 million
  • Year-over-Year Working Capital Change: 14.6% increase
  • Net Working Capital Ratio: 0.85

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow ($3.4 million)
Investing Cash Flow ($1.2 million)
Financing Cash Flow $4.6 million

Liquidity Concerns and Strengths

  • Cash and Cash Equivalents: $2.1 million
  • Short-Term Debt Obligations: $3.5 million
  • Debt-to-Equity Ratio: 1.42



Is NanoVibronix, Inc. (NAOV) Overvalued or Undervalued?

Valuation Analysis

As of 2024, NanoVibronix, Inc. financial valuation metrics reveal critical insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 0.73
Enterprise Value/EBITDA -8.45
Current Stock Price $0.35

Stock price performance metrics include:

  • 52-week low: $0.24
  • 52-week high: $0.75
  • Price volatility: 7.2%

Analyst recommendations breakdown:

Recommendation Percentage
Buy 33.3%
Hold 50%
Sell 16.7%



Key Risks Facing NanoVibronix, Inc. (NAOV)

Risk Factors

NanoVibronix, Inc. faces several critical risk factors that could impact its financial performance and strategic objectives:

Financial Risks

Risk Category Specific Risk Potential Impact
Liquidity Risk Cash Burn Rate $3.2 million quarterly operating expenses
Capital Requirements Potential Additional Funding Needs $5.7 million estimated future capital requirements

Operational Risks

  • Limited product portfolio concentration
  • Dependence on medical device market
  • Regulatory compliance challenges

Market Risks

Key market-related risks include:

  • Intense competition in medical technology sector
  • Potential reimbursement policy changes
  • Technology obsolescence risks

Regulatory Risks

Regulatory Area Potential Risk Compliance Challenge
FDA Approval Process Potential Rejection 18-24 months typical review timeline
Medical Device Regulations Compliance Costs $450,000 estimated annual compliance expenses

Strategic Risks

Strategic risks encompass multiple dimensions:

  • Limited international market penetration
  • Intellectual property protection challenges
  • Potential supply chain disruptions

Financial Performance Risks

Financial performance risks include:

  • Revenue volatility
  • Gross margin fluctuations
  • Research and development investment requirements



Future Growth Prospects for NanoVibronix, Inc. (NAOV)

Growth Opportunities

NanoVibronix, Inc. exhibits potential growth trajectories through strategic market positioning and innovative medical technology developments.

Key Growth Drivers

  • Medical device market projected to reach $603.5 billion by 2027
  • Ultrasound therapeutic technology segment expected to grow at 7.2% CAGR
  • Expanding therapeutic applications in wound care and pain management

Revenue Growth Projection

Year Projected Revenue Growth Rate
2024 $4.2 million 12.5%
2025 $5.1 million 21.4%
2026 $6.3 million 23.5%

Strategic Initiatives

  • Expanding FDA-approved product portfolio
  • Targeting international healthcare markets
  • Investing $1.2 million in R&D for new therapeutic technologies

Competitive Advantages

Unique ultrasound-based therapeutic platform with proven clinical efficacy in multiple medical applications.

Advantage Market Impact
Proprietary Technology Differentiated market positioning
Clinical Validation Enhanced market credibility
Cost-Effective Solutions Attractive to healthcare providers

DCF model

NanoVibronix, Inc. (NAOV) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.